3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
cyclopia sequence
14
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Multiple Myeloma
3
Breast Neoplasms
3
Pain
2
Neoplasms, Plasma Cell
2
Head and Neck Neoplasms
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Thromboembolism
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Sleepiness
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Cognitive Complications
1
Peripheral Nervous System Diseases
1
Peptic Ulcer
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Parasomnias
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
Minocycline
×
Clear all
NCT02928692
2020-01-28
MAPOCD
RenJi Hospital
Phase 3
Unknown
750 enrolled